Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines

Rita Ötvös, Henriette Skribek, Lorand L. Kis, Annunziata Gloghini, Laszlo Markasz, Emilie Flaberg, Staffan Eksborg, Jozsef Konya, Lajos Gergely, Antonino Carbone, Laszlo Szekely

Research output: Contribution to journalArticle

Abstract

Background: Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.Methods: We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.Results: All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.Conclusions: We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.

Original languageEnglish
Article number441
JournalBMC Cancer
Volume11
DOIs
Publication statusPublished - Oct 12 2011

Fingerprint

Lymphoma
Cell Line
Pharmaceutical Preparations
Primary Effusion Lymphoma
Drug Therapy
Non-Hodgkin's Lymphoma
Human Herpesvirus 8
Epirubicin
Daunorubicin
Survival
Kaposi's Sarcoma
Cytostatic Agents
Clinical Protocols
Paclitaxel
Confocal Microscopy
Immunosuppression
B-Lymphocytes
Survival Rate
HIV
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Ötvös, R., Skribek, H., Kis, L. L., Gloghini, A., Markasz, L., Flaberg, E., ... Szekely, L. (2011). Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. BMC Cancer, 11, [441]. https://doi.org/10.1186/1471-2407-11-441

Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. / Ötvös, Rita; Skribek, Henriette; Kis, Lorand L.; Gloghini, Annunziata; Markasz, Laszlo; Flaberg, Emilie; Eksborg, Staffan; Konya, Jozsef; Gergely, Lajos; Carbone, Antonino; Szekely, Laszlo.

In: BMC Cancer, Vol. 11, 441, 12.10.2011.

Research output: Contribution to journalArticle

Ötvös, R, Skribek, H, Kis, LL, Gloghini, A, Markasz, L, Flaberg, E, Eksborg, S, Konya, J, Gergely, L, Carbone, A & Szekely, L 2011, 'Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines', BMC Cancer, vol. 11, 441. https://doi.org/10.1186/1471-2407-11-441
Ötvös, Rita ; Skribek, Henriette ; Kis, Lorand L. ; Gloghini, Annunziata ; Markasz, Laszlo ; Flaberg, Emilie ; Eksborg, Staffan ; Konya, Jozsef ; Gergely, Lajos ; Carbone, Antonino ; Szekely, Laszlo. / Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. In: BMC Cancer. 2011 ; Vol. 11.
@article{ff6d53618ba349b78c3a3766701927bc,
title = "Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines",
abstract = "Background: Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.Methods: We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.Results: All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.Conclusions: We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.",
author = "Rita {\"O}tv{\"o}s and Henriette Skribek and Kis, {Lorand L.} and Annunziata Gloghini and Laszlo Markasz and Emilie Flaberg and Staffan Eksborg and Jozsef Konya and Lajos Gergely and Antonino Carbone and Laszlo Szekely",
year = "2011",
month = "10",
day = "12",
doi = "10.1186/1471-2407-11-441",
language = "English",
volume = "11",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines

AU - Ötvös, Rita

AU - Skribek, Henriette

AU - Kis, Lorand L.

AU - Gloghini, Annunziata

AU - Markasz, Laszlo

AU - Flaberg, Emilie

AU - Eksborg, Staffan

AU - Konya, Jozsef

AU - Gergely, Lajos

AU - Carbone, Antonino

AU - Szekely, Laszlo

PY - 2011/10/12

Y1 - 2011/10/12

N2 - Background: Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.Methods: We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.Results: All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.Conclusions: We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.

AB - Background: Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.Methods: We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.Results: All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.Conclusions: We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=80053901566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053901566&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-11-441

DO - 10.1186/1471-2407-11-441

M3 - Article

C2 - 21992895

AN - SCOPUS:80053901566

VL - 11

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 441

ER -